Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX) to Ring The Nasdaq Stock Market Closing Bell
April 17 2015 - 10:00AM
What:
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical
stage biopharmaceutical company dedicated to developing innovative
medicines for hyperkinetic movement disorders and other rare
diseases, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Pratik Shah, Chief Executive
Officer, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Monday, April 20, 2015 – 3:45 p.m. to 4:00 p.m.
ET
Auspex Pharmaceuticals, Inc. Media Contact:Dan
Budwick, Pure Communications, Inc.(973)
271-6085dan@purecommunicationsinc.com
Nasdaq MarketSite:Christine Barna(646)
441-5310Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About Auspex Pharmaceuticals,
Inc. (Nasdaq:ASPX):
Auspex Pharmaceuticals is a late-clinical stage
biopharmaceutical company dedicated to developing innovative
medicines for hyperkinetic movement disorders and other rare
diseases. Auspex employs its proprietary technology to create
patent-protected, new chemical entities from known, clinically
proven therapies. The company's lead product, SD-809
(deutetrabenazine), is in final stages of development for the
treatment of chorea associated with Huntington's disease, a
neurodegenerative movement disorder that impacts cognition,
behavior and movements. In addition, Auspex is investing in the
broad potential of SD-809 for the treatment of other movement
disorders, including tardive dyskinesia and tics associated with
Tourette's syndrome. The company's pipeline also includes SD-560,
being developed for fibrotic conditions, and SD-1077, which is
being developed for Parkinson's disease. For further information,
please visit the company's website www.auspexpharma.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of over $9.1 trillion and more than 10,000
corporate clients. To learn more, visit www.nasdaq.com/ambition or
www.business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024